Result 2: Taking into account these linear correlations between PK and physiological parameters we have predicted inter-individual variability in pharmacokinetics in more accurate manner.

Result 3: Using the model we have found that standard multiple dosing schedule is not appropriate for some patients. For example, in framework of standard dosing schedule two patients (patient N1 and patient N2) would receive one 25 μM dosage daily. This treatment would go quite well for patient N1 BUT for patient N2 concentration of the drug X has never reached therapeutic level and it has been almost always higher than toxic level.

Result 4: MBDDA enables us to predict optimal multiple dosing schedule which is appropriate for patient N2. Indeed, we have discovered that administration of one 40 μM dosage per 36 hours (1) allows drug X to reach therapeutic concentrations and (2) decreases time periods with its toxic concentrations.